Pneumococcal conjugate vaccine 13 delivered as one primary and one booster dose (1 + 1) compared with two primary doses and a booster (2 + 1) in UK infants: a multicentre, parallel group randomised controlled trial
<p><b>Background:</b> Infants in the UK were first offered a pneumococcal conjugate vaccine (PCV7) in 2006, given at 2 and 4 months of age and a booster dose at 13 months (2 + 1 schedule). A 13-valent vaccine (PCV13) replaced PCV7 in 2010. We aimed to compare the post-booster anti...
Main Authors: | Goldblatt, D, Southern, J, Andrews, N, Burbidge, P, Partington, J, Roalfe, L, Valente Pinto, M, Thalasselis, V, Plested, E, Richardson, H, Snape, M, Miller, E |
---|---|
Format: | Journal article |
Language: | English |
Published: |
Lancet
2017
|
Similar Items
-
Will booster doses be required for serogroup B meningococcal vaccine?
by: McQuaid, F, et al.
Published: (2014) -
Comparison of pneumococcal conjugate vaccine (PCV-13) cellular immune responses after primary and booster doses of vaccine
by: Timothy J. Chapman, et al.
Published: (2020-12-01) -
The antibody response following a booster with either a 10- or 13-valent pneumococcal conjugate vaccine in toddlers primed with a 13-valent pneumococcal conjugate vaccine in early infancy.
by: Trück, J, et al.
Published: (2016) -
Use of a booster dose of capsular group C meningococcal glycoconjugate vaccine to demonstrate immunologic memory in children primed with one or two vaccine doses in infancy
by: Pace, D, et al.
Published: (2016) -
Booster Dose of COVID 19 and Ethical Issues
by: Adeela Shahid
Published: (2021-12-01)